Evidence-based cannabis information for adults 50 and older Peer-reviewed citations · Always talk to your doctor or pharmacist · No product sales

Cannabis & Blood Thinners — Warfarin, Eliquis, Xarelto

Warfarin INR has risen above 10 with concurrent CBD use. Documented case reports, why apixaban and rivaroxaban appear lower-risk, and the INR monitoring schedule.

The Highest-Stakes Cannabis Interaction

Of all the drug interactions between cannabis and prescription medications, blood thinners demand the highest vigilance. Warfarin (brand name Coumadin) has a narrow therapeutic index — the margin between an effective dose and a dangerous one is razor-thin. Small changes in how quickly warfarin is metabolized can tip a patient from therapeutic anticoagulation into life-threatening bleeding.

A 2023 systematic review by Smythe and colleagues in Pharmacotherapy identified seven published case reports of cannabis-warfarin interactions, with INR increases ranging from +0.4 to +9.61 and hemorrhage documented in one case. Strong evidence

If you take warfarin and are considering cannabis in any form, this page explains what the research shows, what can go wrong, and exactly what steps to take to protect yourself.

How the Interaction Works: CYP2C9

Warfarin is primarily broken down in the liver by an enzyme called CYP2C9. CBD is a potent inhibitor of this enzyme. When CBD blocks CYP2C9 activity, warfarin is cleared from the body more slowly. The result: warfarin accumulates in the bloodstream, anticoagulant effect intensifies, and the INR (International Normalized Ratio) rises.

INR is the standard measure of how effectively warfarin is thinning your blood. For most patients, the target range is 2.0 to 3.0. An INR above 4.0 indicates a significantly elevated bleeding risk. An INR above 9.0 is a medical emergency.

THC is also a moderate CYP2C9 inhibitor, meaning both major cannabinoids can contribute to this interaction — not just CBD. Moderate evidence

What the Case Reports Show

Three published cases illustrate the range of this interaction — from dangerous to apparently benign — and underscore that dose matters.

Case 1: CBD at Therapeutic Doses — INR 6.86

A 44-year-old patient on stable warfarin therapy began pharmaceutical CBD (Epidiolex) at 5 mg/kg/day for epilepsy. The INR rose to 6.86 — more than double the upper end of the therapeutic range. The patient's warfarin dose had to be reduced by 30% to restore safe anticoagulation.

Grayson et al., Epilepsy & Behavior Case Reports, 2018

Case 2: Increased Cannabis Smoking — INR Above 10

A 56-year-old patient who had been on stable warfarin for 11 years increased their marijuana smoking. The INR rose above 10 on two separate occasions, accompanied by bleeding events that required vitamin K reversal — an emergency intervention to counteract excessive anticoagulation.

Yamreudeewong et al., Annals of Pharmacotherapy

Case 3: Micro-Dose Cannabis — No INR Change

An 85-year-old patient on warfarin used micro-dose medical cannabis at just 0.3 mg THC + 5.3 mg CBD daily. This patient showed no measurable INR change, suggesting that the interaction is dose-dependent and that very low cannabinoid doses may not produce clinically significant effects on warfarin metabolism. Limited evidence

Thomas et al., Journal of Cannabis Research, 2022

Newer Blood Thinners: Apixaban & Rivaroxaban

The direct oral anticoagulants (DOACs) — apixaban (Eliquis) and rivaroxaban (Xarelto) — work differently from warfarin and are metabolized by CYP3A4 rather than CYP2C9. Because the strongest warfarin interaction mechanism (CYP2C9 inhibition) does not apply, the risk profile is theoretically lower. ⚠️ Emerging

As of the 2023 Smythe systematic review, no case reports of cannabis-DOAC interactions have been published. However, CBD does inhibit CYP3A4 — the enzyme that metabolizes these drugs — so a theoretical interaction remains plausible. The absence of case reports does not mean the interaction cannot occur; it means it has not yet been formally documented.

If you take a DOAC and are considering cannabis, the risk is likely lower than with warfarin, but you should still discuss it with your prescribing physician and pharmacist.

If You Take Warfarin: Action Checklist

Follow these steps before starting, stopping, or changing any cannabis product while on warfarin:

  1. Tell your anticoagulation clinic. Inform them you are considering cannabis (or already using it). They manage your INR schedule and warfarin dosing — they need this information to keep you safe.
  2. Request weekly INR monitoring. During the first 4–6 weeks of any change in cannabis use, your INR should be checked at least weekly. This applies whether you are starting, increasing, decreasing, or stopping cannabis.
  3. Bring your cannabis product label. Show your pharmacist the exact product, including milligrams of THC and CBD per dose. Different products have vastly different cannabinoid concentrations.
  4. Start with the lowest possible dose. If your medical team agrees that a trial is appropriate, begin with a micro-dose and increase slowly. The start low, go slow principle is especially critical here.
  5. Do not change cannabis and warfarin doses simultaneously. If your warfarin dose is being adjusted, hold your cannabis dose constant (and vice versa). Changing both at once makes it impossible to determine which variable is affecting your INR.
  6. Watch for bleeding signs. Unusual bruising, blood in urine or stool, nosebleeds that will not stop, bleeding gums, or sudden severe headache — these all require immediate medical attention.
  7. Consider topicals. Cannabis topicals (creams, balms) produce negligible systemic absorption and are not expected to cause drug interactions. For localized pain relief, they may be the safest option for warfarin patients. See Topicals.

Related Pages